{"id":8187,"date":"2020-12-07T03:57:24","date_gmt":"2020-12-07T03:57:24","guid":{"rendered":"http:\/\/ncjolt.org\/?p=8187"},"modified":"2020-12-07T03:57:24","modified_gmt":"2020-12-07T03:57:24","slug":"redefining-the-trips-agreement-to-accommodate-en-masse-compulsory-licensing-of-vaccines-other-pharmaceuticals-for-the-treatment-of-covid-19","status":"publish","type":"post","link":"https:\/\/journals.law.unc.edu\/ncjolt\/articles\/volume-22\/volume-22-issue-2\/redefining-the-trips-agreement-to-accommodate-en-masse-compulsory-licensing-of-vaccines-other-pharmaceuticals-for-the-treatment-of-covid-19\/","title":{"rendered":"REDEFINING THE TRIPS AGREEMENT TO ACCOMMODATE EN MASSE COMPULSORY LICENSING OF VACCINES &amp; OTHER PHARMACEUTICALS FOR THE TREATMENT OF COVID-19"},"content":{"rendered":"<a href=\"https:\/\/journals.law.unc.edu\/ncjolt\/wp-content\/uploads\/sites\/4\/2020\/12\/NCJOLT-Vol.22.2_4_Farquhar.pdf\" class=\"pdfemb-viewer\" style=\"\" data-width=\"max\" data-height=\"max\" data-mobile-width=\"500\"  data-scrollbar=\"none\" data-download=\"off\" data-tracking=\"on\" data-newwindow=\"on\" data-pagetextbox=\"off\" data-scrolltotop=\"off\" data-startzoom=\"100\" data-startfpzoom=\"100\" data-toolbar=\"bottom\" data-toolbar-fixed=\"off\">NCJOLT-Vol.22.2_4_Farquhar<br\/><\/a>\n<p class=\"wp-block-pdfemb-pdf-embedder-viewer\"><\/p>\n\n\n\n<p><em>Globally, over 48 million cases and over one million deaths have resulted from the COVID-19 pandemic at the time of this publication. Governments and pharmaceutical companies are simultaneously racing for effective treatments and vaccines against the deadly virus, giving rise to a vaccine nationalism in effort to claim a global monopoly on recovery. This Article analyzes the possible compulsory licensing fallout over COVID-19 vaccines and pharmaceuticals under the current terms of the TRIPS Agreement, advocating for clarifying the ambiguous language of TRIPS, creating a standardized compensation scheme to patent holders, and developing a third-party arbitration mechanism to specifically address compulsory licensing disputes over COVID-19 pharmaceuticals and vaccines. These proposed solutions aim to balance the interests of patent holders with the interests of the global population.<\/em><\/p>\n\n\n\n<p><strong>Author: Alexandra H. Farquhar<\/strong><\/p>\n\n\n\n<p><strong>PDF:<\/strong> http:\/\/journals.law.unc.edu\\\/ncjolt\/wp-content\/uploads\/sites\/4\/2020\/12\/NCJOLT-Vol.22.2_4_Farquhar.pdf <\/p>\n\n\n\n<p><strong>Volume 22, Issue 2 <\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Globally, over 48 million cases and over one million deaths have resulted from the COVID-19 pandemic at the time of this publication. Governments and pharmaceutical companies are simultaneously racing for effective treatments and vaccines against the deadly virus, giving rise to a vaccine nationalism in effort to claim a global monopoly on recovery. This Article <a href=\"https:\/\/journals.law.unc.edu\/ncjolt\/articles\/volume-22\/volume-22-issue-2\/redefining-the-trips-agreement-to-accommodate-en-masse-compulsory-licensing-of-vaccines-other-pharmaceuticals-for-the-treatment-of-covid-19\/\" class=\"more-link\">&#8230;<\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[138],"tags":[],"_links":{"self":[{"href":"https:\/\/journals.law.unc.edu\/ncjolt\/wp-json\/wp\/v2\/posts\/8187"}],"collection":[{"href":"https:\/\/journals.law.unc.edu\/ncjolt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/journals.law.unc.edu\/ncjolt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/journals.law.unc.edu\/ncjolt\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/journals.law.unc.edu\/ncjolt\/wp-json\/wp\/v2\/comments?post=8187"}],"version-history":[{"count":1,"href":"https:\/\/journals.law.unc.edu\/ncjolt\/wp-json\/wp\/v2\/posts\/8187\/revisions"}],"predecessor-version":[{"id":8189,"href":"https:\/\/journals.law.unc.edu\/ncjolt\/wp-json\/wp\/v2\/posts\/8187\/revisions\/8189"}],"wp:attachment":[{"href":"https:\/\/journals.law.unc.edu\/ncjolt\/wp-json\/wp\/v2\/media?parent=8187"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/journals.law.unc.edu\/ncjolt\/wp-json\/wp\/v2\/categories?post=8187"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/journals.law.unc.edu\/ncjolt\/wp-json\/wp\/v2\/tags?post=8187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}